Evidence map›Paper›PMID 41540371›Full record

ReviewCell communication and signaling : CCS2026

Unlocking neuronal health: leveraging C. elegans for drug repurposing studies.

Spoorthy Gowda, Arun Kumar, Ulrike Topf

Abstract readReview
In one paragraph

Review in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Spoorthy GowdaLaboratory of Molecular Basis of Aging and Rejuvenation, Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Pawińskiego 5a, Warsaw, 02-106, Poland.
Arun KumarLaboratory of Molecular Basis of Aging and Rejuvenation, Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Pawińskiego 5a, Warsaw, 02-106, Poland.
Ulrike TopfLaboratory of Molecular Basis of Aging and Rejuvenation, Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Pawińskiego 5a, Warsaw, 02-106, Poland. utopf@ibb.waw.pl.

Funding

Narodowe Centrum Nauki 2022/45/B/NZ1/03714
6 · The paper itself

Abstract

Aging affects neuronal function, leading to both structural and functional changes in the human brain. The concomitant cognitive decline and neurodegenerative diseases drive efforts to find pharmaceutical drugs to ameliorate the consequences of neuron-associated deficits during aging. C. elegans is an excellent model to combine studies of the nervous system and drug screening. C. elegans has a well-characterized and relatively simple nervous system that allows for precise mapping of neuronal circuits. Neuronal activity plays a crucial role in regulating lifespan in C. elegans. Various genetic, environmental, and pharmacological factors modulate neuronal signaling, affecting longevity by activating cell non-autonomous mechanisms in other tissues. Drug repurposing through screening approved human drugs in model organisms is an increasingly applied approach to identify off-label therapeutic effects. This review discusses research in C. elegans that applied drugs as neuromodulators with the aim to increase lifespan and healthspan. We focused on drugs with confirmed anticonvulsant, antidepressant, antipsychotic, antihypertensive, or anti-inflammatory properties. This review highlights potential mechanisms of how such drugs can exert a beneficial effect during organismal aging. Future research must intensify efforts to not only demonstrate a beneficial effect of repurposed drugs, but more importantly, to elucidate the underlying cellular responses. This will be essential for advancing selected drugs that have the potential for conserved benefit in humans.

Indexed as

Caenorhabditis elegansDrug RepositioningNeuronsAgingAnimalsHumansLongevityAnticonvulsantAntidepressantC. elegansDrug repurposingHealthspanNervous systemNSAID

Identifiers

PMID41540371
PMCPMC12892455

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.